Dengue vaccine study
Tuesday, 02 September, 2008
Avantogen [ASX: ACU] investee Hawaii Biotech will receive clinical trial support from the US Walter Reed Army Institute of Research (WRAIR) for its dengue fever vaccine program.
WRAIR has considerable experience with dengue fever and an established track record in emerging infectious diseases.
The recombinant-DNA-based vaccine candidate will soon undertake the clinical trial process.
Incidents of dengue, a close relative of the West Nile virus, are now growing rapidly in Australia and the Asian region.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
